2-氯-3-甲基-4-氟苯甲腈 | 796600-15-2

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯腈系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-3-甲基-4-氟苯甲腈
• 中文别名: 2-甲基-3-氯-4-氰基氟苯；2-氯-4-氟-3-甲基苯甲腈
• 英文名称: 2-chloro-4-fluoro-3-methylbenzonitrile
• CAS: 796600-15-2
• 化学式: C₈H₅ClFN
• 分子量: 169.586
• InChiKey: IOKBJSAKTZEMBR-UHFFFAOYSA-N

物化性质

• 熔点：
  54-58°C
• 沸点：
  260.8±35.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Chloro-4-fluoro-3-methylbenzonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Chloro-4-fluoro-3-methylbenzonitrile
CAS number: 796600-15-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H5ClFN
Molecular weight: 169.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-3-甲基-4-氟苯甲腈 在 potassium carbonate 、 potassium hydroxide 作用下， 以 乙醚 、 二甲基亚砜 为溶剂， 反应 36.5h， 生成 (2R,3S)-methyl-2-(3-chloro-4-cyano-2-methylphenylamino)-3-hydroxybutanoate
  参考文献：
  名称：

  [EN] SELECTIVE ANDROGEN RECEPTOR MODULATORS
  [FR] MODULATEURS SÉLECTIFS DU RÉCEPTEUR DES ANDROGÈNES

  摘要：

  该发明提供了公式I的化合物，包括公式I化合物和药学上可接受的赋形剂的药物组合物，调节雄激素受体的方法，治疗通过雄激素受体调节剂有益治疗的疾病的方法（例如，肌少症、前列腺癌、避孕、与2型糖尿病相关的疾病或疾病、贫血、抑郁症和肾脏疾病），以及制备用于制备相同物质的化合物和中间体的过程。

  公开号：

  WO2012047617A1
• 作为产物：
  描述：

  2-chloro-4-fluoro-3-methylbenzamide 在 吡啶 、 草酰氯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 2-氯-3-甲基-4-氟苯甲腈
  参考文献：
  名称：

  WO2007/15567

  摘要：

  公开号：
• 作为试剂：
  描述：

  lithium diisopropyl amide 、 2-氯-4-氟苯腈 、 碘甲烷 、 ethyl acetate n-hexane 在 氯化铵 、 水 、 乙醚 、 layer 、 magnesium sulfate 、 2-氯-3-甲基-4-氟苯甲腈 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 37.0h， 以to afford the crude title compound as a red-brown oily solid (about 86.7 g)的产率得到2-氯-3-甲基-4-氟苯甲腈
  参考文献：
  名称：

  Substituted N-arylpyrrolidines as selective androgen receptor modulators

  摘要：

  本发明提供了式（I）的化合物或其药学上可接受的盐；包含式（I）化合物的有效量与适当载体、稀释剂或赋形剂组合的药物组合物；以及治疗生理障碍，特别是衰弱、骨质疏松症、骨质疏松和男女性功能障碍的方法，包括向需要该药物的患者施用式（I）化合物的有效量。

  公开号：

  US07807691B2

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS ET COMPOSITIONS UTILISÉS POUR TRAITER LES MALADIES NEURODÉGÉNÉRATIVES
  申请人：ACADIA PHARM INC

  公开号：WO2014125121A1

  公开（公告）日：2014-08-21

  The present application relates to a composition comprising a selective androgen modulating compound of formula (I) and selective estrogen receptor β agonist of formula (II). The present application also relates to the use of a selective androgen modulating compound of formula (I) in combination with a selective estrogen receptor β agonist of formula (II) in the treatment or prevention of neurodegenerative diseases or disorders,such as Alzheimer's disease, Huntigton's disease, Parkinson's disease, depression, anxiety, multiple sclerosis, symptoms associated with or caused by multiple sclerosis, and acute or chronic pain.

  本申请涉及一种包含公式（I）的选择性雄激素调节化合物和公式（II）的选择性雌激素受体β激动剂的组合物。本申请还涉及将公式（I）的选择性雄激素调节化合物与公式（II）的选择性雌激素受体β激动剂结合使用，用于治疗或预防神经退行性疾病或障碍，例如阿尔茨海默病、亨廷顿病、帕金森病、抑郁症、焦虑症、多发性硬化症、与多发性硬化症相关或由其引起的症状，以及急性或慢性疼痛。
• Selective androgen receptor modulators
  申请人：Miller Chris P.

  公开号：US20090253758A1

  公开（公告）日：2009-10-08

  This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, and or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, Ie, and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor modulator (e.g., sarcopenia, prostate cancer, contraception, type 2 diabetes related disorders or diseases, anemia, depression, and renal disease) and processes for making compounds of formulas I, Ia, Ib, Ic, Id, Ie, and intermediates useful in the preparation of same.

  本发明提供了公式I、Ia、Ib、Ic、Id、Ie的化合物，以及它们的盐，包含这些化合物的药物组合物和药用辅料，调节雄激素受体方法，治疗可受益于雄激素受体调节剂（例如，肌肉减少症、前列腺癌、避孕、2型糖尿病相关疾病或病症、贫血、抑郁和肾脏疾病）的疾病的方法，以及制造公式I、Ia、Ib、Ic、Id、Ie的化合物和用于制备这些化合物的中间体的过程。
• [EN] SELECTIVE ANDROGEN RECEPTOR MODULATORS<br/>[FR] MODULATEURS SÉLECTIFS D'UN RÉCEPTEUR DES ANDROGÈNES
  申请人：LILLY CO ELI

  公开号：WO2013055577A1

  公开（公告）日：2013-04-18

  The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.

  本发明提供了新型选择性雄激素受体调节剂及其盐和药物组合物。
• OXAZOLIDINE-BASED COMPOUND AND SELECTIVE ANDROGEN RECEPTOR AGONIST COMPRISING SAME
  申请人：Dong-A ST Co., Ltd.

  公开号：EP3135669A1

  公开（公告）日：2017-03-01

  Provided are novel selective androgen receptor agonists, a preparation method thereof, and a pharmaceutical composition including the same at a pharmaceutically effective amount. The selective androgen receptor agonists according to the present invention act on androgen receptors to increase androgen activity, thereby being usefully applied as a therapeutic and prophylactic agent for diseases or conditions, of which symptoms may be improved or may respond to treatment by increased activities of androgen receptors, namely, a variety of hormone-related diseases in male and female, muscle wasting disorders, osteoporosis, etc.

  提供了一种新型选择性雄激素受体激动剂，以及其制备方法和包括其在内的药物组合物，所述药物组合物在药学有效量下。根据本发明的选择性雄激素受体激动剂作用于雄激素受体以增加雄激素活性，因此可作为治疗和预防剂用于疾病或症状，其症状可能通过增加雄激素受体活性得到改善或可能对治疗产生反应，即男性和女性的各种激素相关疾病，肌肉消耗性疾病，骨质疏松症等。
• Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs
  作者：Ting-Ting Li、Christophe Pannecouque、Erik De Clercq、Chun-Lin Zhuang、Fen-Er Chen

  DOI：10.3390/molecules25071581

  日期：——

  Scaffold hopping is a frequently-used strategy in the development of non-nucleoside reverse transcriptase inhibitors. Herein, CH(CN)-DAPYs were designed by hopping the cyano-methylene linker of our previous published CH(CN)-DABOs onto the etravirine (ETR). Eighteen CH(CN)-DAPYs were synthesized and evaluated for their anti-HIV activity. Most compounds exhibited promising activity against wild-type

  支架跳跃是开发非核苷逆转录酶抑制剂的常用策略。在此，CH(CN)-DAPYs 是通过将我们之前发表的 CH(CN)-DABOs 的氰基-亚甲基连接基跳跃到依曲韦林 (ETR) 上来设计的。合成了 18 个 CH(CN)-DAPY，并评估了它们的抗 HIV 活性。大多数化合物对野生型 (WT) HIV-1 表现出有希望的活性。化合物 B4 (EC50 = 6 nM) 和 B6 (EC50 = 8 nM) 显示出对 WT HIV-1 的个位数纳摩尔效力。此外，这两种化合物对 K103N 突变体的 EC50 值分别为 0.06 和 0.08 μM，与参照依非韦伦 (EFV) (EC50 = 0.08 μM) 相当。初步构效关系 (SAR) 表明在 4-氰基苯基的 C2 上引入取代可以提高抗病毒活性。